Area of research
Pathology and Forensic Medicine · Genetics
Research interest
Research interests include Medicine, Bendamustine, Salvage therapy, Brentuximab vedotin, Regimen, and Internal medicine.
Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
Mogamulizumab <i>versus</i> investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma
A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Investigator's Choice in the Treatment of Patients with Relapsed/Refractory Adult T-Cell Leukemia-Lymphoma: Overall Response Rate, Progression-Free Survival, and Overall Survival
Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma